Literature DB >> 11980633

Regulation of microtubule stability and mitotic progression by survivin.

Alessandra Giodini1, Marko J Kallio, Nathan R Wall, Gary J Gorbsky, Simona Tognin, Pier Carlo Marchisio, Marc Symons, Dario C Altieri.   

Abstract

Survivin is a member of the inhibitor of apoptosis (IAP) gene family, which has been implicated in both preservation of cell viability and regulation of mitosis in cancer cells. Here, we show that HeLa cells microinjected with a polyclonal antibody to survivin exhibited delayed progression in prometaphase (31.5 +/- 6.9 min) and metaphase (126.8 +/- 73.8 min), as compared with control injected cells (prometaphase, 21.5 +/- 3.3 min; metaphase, 18.9 +/- 4.5 min; P < 0.01). Cells injected with the antibody to survivin displayed short mitotic spindles severely depleted of microtubules and occasionally underwent apoptosis without exiting the mitotic block or thereafter. Forced expression of survivin in HeLa cells profoundly influenced microtubule dynamics with reduction of pole-to-pole distance at metaphase (8.57 +/- 0.21 microm versus 10.58 +/- 0.19 microm; P < 0.0001) and stabilization of microtubules against nocodazole-induced depolymerization in vivo. These data demonstrate that survivin functions at cell division to control microtubule stability and assembly of a normal mitotic spindle. This pathway may facilitate checkpoint evasion and promote resistance to chemotherapy in cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11980633

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  71 in total

1.  Cell division and cell survival in the absence of survivin.

Authors:  Dun Yang; Alana Welm; J Michael Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

2.  Survivin is a potential mediator of prostate cancer metastasis.

Authors:  Min Zhang; John J Coen; Yoshiyuki Suzuki; Michael R Siedow; Andrzej Niemierko; Li-Yan Khor; Alan Pollack; Yifen Zhang; Anthony L Zietman; William U Shipley; Arnab Chakravarti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-16       Impact factor: 7.038

3.  Relationship of survivin to clinical drug resistance in Burkitt's lymphoma of the head and neck region.

Authors:  Manal M Zyada
Journal:  Med Oncol       Date:  2010-06-04       Impact factor: 3.064

4.  Cytoplasmic LEK1 is a regulator of microtubule function through its interaction with the LIS1 pathway.

Authors:  Victor Soukoulis; Samyukta Reddy; Ryan D Pooley; Yuanyi Feng; Christopher A Walsh; David M Bader
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

5.  Survivin modulates microtubule dynamics and nucleation throughout the cell cycle.

Authors:  Jack Rosa; Pedro Canovas; Ashraful Islam; Dario C Altieri; Stephen J Doxsey
Journal:  Mol Biol Cell       Date:  2006-01-11       Impact factor: 4.138

Review 6.  Induction of apoptosis in lymphoid and myeloid leukemia.

Authors:  Aaron D Schimmer
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

7.  Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis.

Authors:  Takehiko Dohi; Elena Beltrami; Nathan R Wall; Janet Plescia; Dario C Altieri
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

Review 8.  Survivin as a novel target protein for reducing the proliferation of cancer cells.

Authors:  Dongyu Li; Chenghao Hu; Huibin Li
Journal:  Biomed Rep       Date:  2018-03-13

9.  Differential insulin-like growth factor II (IGF-II) expression: A potential role for breast cancer survival disparity.

Authors:  S Kalla Singh; Q W Tan; C Brito; M De León; C Garberoglio; D De León
Journal:  Growth Horm IGF Res       Date:  2010-01-25       Impact factor: 2.372

10.  Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer.

Authors:  Chan H Han; Qingyi Wei; Karen K Lu; Zhensheng Liu; Gordon B Mills; Li-E Wang
Journal:  Int J Clin Exp Med       Date:  2009-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.